Park J S, Rhyu K S, Kim C J, Kim H S, Han K T, Ahn H K, Kim S J, Namkoong S E
Department of Obstetrics and Gynecology, Catholic University Medical College, Seoul, Korea.
Gynecol Oncol. 1996 Mar;60(3):418-23. doi: 10.1006/gyno.1996.0066.
The presence of oncogenic HPV DNAs (HPV-16/18) in cervical carcinomas and their normal and metastatic pelvic lymph nodes and the expression patterns of proliferating cell nuclear antigen (PCNA) in cervical carcinomas were retrospectively studied to elucidate the possible roles of them in malignant transformation and progression of the disease. HPV-16/18 DNAs were detected by polymerase chain reaction using HPV E6 type-specific primers in 79 patients with cervical cancer. 31 patients who had pelvic lymph node metastasis (group I) and 48 patients without pelvic lymph node metastasis (group II) who were proven by pathologic examination of surgical specimens. HPV-16 or -18 DNAs were detectable in cervical carcinoma tissues in 60 patients from 79 cervical cancer patients (75.9%; HPV-16 was 67.1% and HPV-18 was 8.9%). HPV DNAs were amplified from metastatic pelvic lymph nodes in 13 patients of group I (42%) and from nonmetastatic lymph nodes in 7 group I patients (22.5%). Recurrence was identified in 9 group I patients (29.0%) in 3 years of follow-up. HPV DNAs were amplified from nonmetastatic lymph nodes in 11 group II patients (22.9%). Two group II patients, who had HPV-16 DNA by PCR in nonmetastatic nodes, were recurrent. PCNA was overexpressed in 66.7% of HPV-16- or -18-positive cervical cancers and 16.7% of HPV-16- or -18-negative cervical cancers. However, the expression levels of PCNA in cervical cancers were not influenced by the presence of oncogenic HPV DNA or pathologic metastasis in the pelvic lymph nodes. In conclusion, HPV DNA could be amplified from some metastatic and nonmetastatic pelvic lymph nodes and the detectability of oncogenic HPV DNA in pelvic lymph nodes may represent the poor outcome in the treatment of disease. The expression of PCNA protein which was associated with presence of oncogenic HPV DNAs in cervical cancers, suggesting activation of S phase of cell cycle, may contribute to the malignant progression by HPV-16 or -18.
回顾性研究宫颈癌及其正常和转移盆腔淋巴结中致癌性人乳头瘤病毒DNA（HPV-16/18）的存在情况以及增殖细胞核抗原（PCNA）在宫颈癌中的表达模式，以阐明它们在疾病恶变和进展中的可能作用。采用HPV E6型特异性引物通过聚合酶链反应检测79例宫颈癌患者的HPV-16/18 DNA。31例有盆腔淋巴结转移的患者（I组）和48例无盆腔淋巴结转移的患者（II组），均经手术标本病理检查证实。79例宫颈癌患者中，60例（75.9%）宫颈癌组织可检测到HPV-16或-18 DNA（HPV-16为67.1%，HPV-18为8.9%）。I组13例患者（42%）转移盆腔淋巴结中扩增出HPV DNA，I组7例患者（22.5%）非转移淋巴结中扩增出HPV DNA。随访3年，I组9例患者（29.0%）复发。II组11例患者（22.9%）非转移淋巴结中扩增出HPV DNA。II组2例非转移淋巴结经PCR检测有HPV-16 DNA的患者复发。PCNA在66.7%的HPV-16或-18阳性宫颈癌和16.7%的HPV-16或-18阴性宫颈癌中过表达。然而，宫颈癌中PCNA的表达水平不受致癌性HPV DNA的存在或盆腔淋巴结病理转移的影响。总之，HPV DNA可从一些转移和非转移盆腔淋巴结中扩增出来，盆腔淋巴结中致癌性HPV DNA的可检测性可能代表疾病治疗效果不佳。PCNA蛋白的表达与宫颈癌中致癌性HPV DNA的存在相关，提示细胞周期S期激活，可能有助于HPV-16或-18导致的恶性进展。
